Compare MPTI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPTI | CGTX |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 110.8M |
| IPO Year | 2022 | 2021 |
| Metric | MPTI | CGTX |
|---|---|---|
| Price | $85.17 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $71.00 | $3.33 |
| AVG Volume (30 Days) | 59.4K | ★ 769.1K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $54,417,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $12.15 | N/A |
| P/E Ratio | $126.79 | ★ N/A |
| Revenue Growth | ★ 11.03 | N/A |
| 52 Week Low | $36.38 | $0.24 |
| 52 Week High | $87.23 | $3.83 |
| Indicator | MPTI | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.04 | 50.80 |
| Support Level | $60.13 | $1.02 |
| Resistance Level | $87.23 | $1.19 |
| Average True Range (ATR) | 4.75 | 0.09 |
| MACD | 0.82 | -0.00 |
| Stochastic Oscillator | 88.90 | 56.00 |
M-Tron Industries Inc is an electronic components manufacturer based in the United States. Along with its subsidiaries, the company is engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company serves markets in aerospace and defense, space, and avionics sectors. Its product offerings include microwave and millimeter-wave filters, crystal resonators, clock oscillators, voltage-controlled crystal oscillators, low noise amplifiers, couplers, attenuators, and switches, among others. Geographically, it derives maximum revenue from the domestic market, and the rest from Malaysia, Australia, Greece, and other countries.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).